Allogene Therapeutics, Inc. (ALLO) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Allogene Therapeutics, Inc. (ALLO) posted $0 in revenue for fiscal 2025 (down 100.0% year over year), with a net loss of $190.89M, per its SEC filings.
Data last refreshed September 3, 2026 from SEC filings · how we compute this
The analyst's take on Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. has grown revenue from — to $0 over the last 8 fiscal years. The most recent year was down 100%.
It clears 1 of 5 deterministic health checks. The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Allogene Therapeutics, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
See a claim about Allogene Therapeutics, Inc.? Check it against the filing
Open the full tool →Paste a headline number you saw about ALLO — a press-release figure, a tweet, another tool’s number — and see the filed SEC number side-by-side with its source. Free, no account.
Allogene Therapeutics, Inc. revenue & earnings — last 8 fiscal years
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $114.09M | $156,000 | $95,000 | $22,000 | $0 |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | $-211.50M | $-184.59M | $-316.38M | $-182.05M | $-340.41M | $-327.26M | $-257.59M | $-190.89M |
| Net margin | — | — | — | -159.6% | -218214.1% | -344489.5% | -1170863.6% | — |
Source: Allogene Therapeutics, Inc. SEC filings (10-K).
Allogene Therapeutics, Inc. financial health: 1 of 5 checks passed
- ✗Profitable every year (last 5)
- ✓More cash than total debt (cash 250.2M vs debt 0M)
- ✗Positive operating cash flow (last 5 yrs)
- ✗Free cash flow positive (latest yr) (-149.6M)
- ✗Share count falling over 5 yrs (buybacks) (140.5M → 229.4M shares)
Checks computed deterministically from filed annual statements — no AI judgement.
Allogene Therapeutics, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 60.9% over 4 years (142.6M → 229.4M) — existing holders' stakes are being diluted.
Explore 8 years of Allogene Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a $24.99/month plan to track ALLO in your portfolio →
Allogene Therapeutics, Inc. financial history
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Allogene Therapeutics, Inc. — frequently asked questions
What is Allogene Therapeutics, Inc.'s revenue?
Allogene Therapeutics, Inc. (ALLO) reported revenue of $0 for fiscal year 2025, down 100.0% from the prior year, according to its SEC filings.
Is Allogene Therapeutics, Inc. profitable?
No — ALLO reported a net loss of $-190.89M in fiscal 2025.
What is Allogene Therapeutics, Inc.'s market cap?
Allogene Therapeutics, Inc. (ALLO) has a market capitalization of about $636.81M, based on the latest data in our nightly-refreshed cache.
When does Allogene Therapeutics, Inc.'s fiscal year end?
ALLO's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Allogene Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.